Trial
NCT05219513
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Lymphoma, Non-Hodgkin
Intervention
RO7443904
Why stopped
The study was terminated due to sponsor portfolio re-alignment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-08-23